10:00 AM EDT, 07/31/2025 (MT Newswires) -- Apellis Pharmaceuticals' ( APLS ) shares climbed by more than 17% in early trading on Thursday after reporting a smaller-than-expected Q2 loss

The biopharmaceutical company reported a Q2 net loss of $0.33 per diluted share, compared with a loss of $0.30 a year earlier. Analysts polled by FactSet expected a loss of $0.44.

Total revenue for the quarter ended June 30 was $178.5 million, down from $199.7 million a year earlier.

Analysts surveyed by FactSet expected $187.7 million.

As of June 30, the company said it had $370 million in cash and cash equivalents.

Price: 21.90, Change: +2.90, Percent Change: +15.24